Arvinas Inc. said the U.S. Food and Drug Administration has granted fast-track designation to ARV-110, an investigational drug for treating men with a certain type of prostate cancer.
The New Haven, Conn.-based company is evaluating the safety and efficacy of ARV-110 in an early-stage study involving male patients with castration-resistant prostate cancer that has spread to other parts of the body and whose disease progressed after receiving two or more systemic therapies.
Prostate cancer is the second-most prevalent cancer in men as well as the second leading cause of death in men in the U.S. The American Cancer Society predicts that one in nine men will be diagnosed with prostate cancer during their lifetime.
Full results of the trial are expected to be available in the first half of 2020.